Evidence map›Paper›PMID 31726669›Full record

ArticleCells2019

Combinatory Multifactor Treatment Effects on Primary Nanofiber Oligodendrocyte Cultures.

Lukas S Enz, Thomas Zeis, Annalisa Hauck, Christopher Linington, Nicole Schaeren-Wiemers

Open access · goldAbstract read
In one paragraph

Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Lukas S EnzNeurobiology, Department of Biomedicine, University Hospital Basel, University Basel, Zentrum für Lehre und Forschung, 4031 Basel, Switzerland.
Thomas ZeisNeurobiology, Department of Biomedicine, University Hospital Basel, University Basel, Zentrum für Lehre und Forschung, 4031 Basel, Switzerland.
Annalisa HauckNeurobiology, Department of Biomedicine, University Hospital Basel, University Basel, Zentrum für Lehre und Forschung, 4031 Basel, Switzerland.ORCID 0000-0002-6853-8363
Christopher LiningtonInstitute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK.
Nicole Schaeren-WiemersNeurobiology, Department of Biomedicine, University Hospital Basel, University Basel, Zentrum für Lehre und Forschung, 4031 Basel, Switzerland.ORCID 0000-0002-6554-4725
University Hospital of Basel · CHUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system. Neurological deficits are attributed to inflammatory demyelination, which compromises axonal function and survival. These are mitigated in experimental models by rapid and often complete remyelination of affected axons, but in MS this endogenous repair mechanism frequently fails, leaving axons increasingly vulnerable to the detrimental effects of inflammatory and metabolic stress. Understanding the molecular basis of remyelination and remyelination failure is essential to develop improved therapies for this devastating disease. However, recent studies suggest that this is not due to a single dominant mechanism, but rather represents the biological outcome of multiple changes in the lesion microenvironment that combine to disrupt oligodendrocyte differentiation. This identifies a pressing need to develop technical platforms to investigate combinatory and/or synergistic effects of factors differentially expressed in MS lesions on oligodendrocyte proliferation and differentiation. Here we describe protocols using primary oligodendrocyte cultures from Bl6 mice on 384-well nanofiber plates to model changes affecting oligodendrogenesis and differentiation in the complex signaling environment associated with multiple sclerosis lesions. Using platelet-derived growth factor (PDGF-AA), fibroblast growth factor 2 (FGF2), bone morphogenetic protein 2 (BMP2) and bone morphogenetic protein 4 (BMP4) as representative targets, we demonstrate that we can assess their combinatory effects across a wide range of concentrations in a single experiment. This in vitro model is ideal for assessing the combinatory effects of changes in availability of multiple factors, thus more closely modelling the situation in vivo and furthering high-throughput screening possibilities.

Indexed as

AnimalsBone Morphogenetic Protein 2Bone Morphogenetic Protein 4Cell DifferentiationCell ProliferationCells, CulturedFibroblast Growth Factor 2HumansMiceModels, TheoreticalMultiple SclerosisMyelin SheathNanofibersOligodendrogliaPlatelet-Derived Growth FactorPrimary Cell CultureBone Morphogenetic Protein 2Bone Morphogenetic Protein 4Fibroblast Growth Factor 2Platelet-Derived Growth Factorplatelet-derived growth factor Amultiple sclerosismyelinnanofibersoligodendrocyteremyelinationscreening

Identifiers

PMID31726669
PMCPMC6912369
OpenAlexW2985771950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.